122 related articles for article (PubMed ID: 34847814)
1. Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer.
Seto Z; Takata N; Murayama N; Tokui K; Okazawa S; Kambara K; Imanishi S; Miwa T; Hayashi R; Matsui S; Inomata M
Tumori; 2021 Dec; 107(6):536-541. PubMed ID: 34847814
[TBL] [Abstract][Full Text] [Related]
2. RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
Spigel DR; Dowlati A; Chen Y; Navarro A; Yang JC; Stojanovic G; Jove M; Rich P; Andric ZG; Wu YL; Rudin CM; Chen H; Zhang L; Yeung S; Benzaghou F; Paz-Ares L; Bunn PA;
J Clin Oncol; 2024 Jul; 42(19):2317-2326. PubMed ID: 38648575
[TBL] [Abstract][Full Text] [Related]
3. Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis.
Imai H; Yamada Y; Minemura H; Sugiyama T; Kotake M; Kaira K; Kanazawa K; Nakamura Y; Kasai T; Shibata Y; Kaburagi T; Minato K;
Thorac Cancer; 2018 Dec; 9(12):1699-1706. PubMed ID: 30281216
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of the Efficacy of Irinotecan in the Second-line Treatment of Refractory and Relapsed Small Cell Lung Cancer].
Xing H; Zhang J; Ge F; Yu X; Bian H; Zhang F; Fang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):167-172. PubMed ID: 33819966
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Irinotecan as Third-line Chemotherapy for Unresectable or Recurrent Gastric Cancer.
Fukuchi M; Kuwabara K; Ishiguro T; Kumagai Y; Ishibashi K; Mochiki E; Ishida H
In Vivo; 2020; 34(2):903-908. PubMed ID: 32111802
[TBL] [Abstract][Full Text] [Related]
6. UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
Bandyopadhyay A; Sharma S; Behera D; Singh N
Oncologist; 2021 Aug; 26(8):701-713. PubMed ID: 33728696
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer.
Fu J; Fang S; Wen Y; Wang Y; Yin X; Wang D
J BUON; 2020; 25(4):1707-1713. PubMed ID: 33099904
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).
Tanaka H; Hasegawa Y; Fujita Y; Nakamura A; Kikuchi E; Kawai Y; Harada T; Watanabe N; Yokouchi H; Usui K; Saito R; Watanabe H; Masuda T; Fukuhara T; Kudo K; Honda R; Oizimi S; Maemondo M; Inoue A; Morikawa N
Thorac Cancer; 2021 Jul; 12(14):2113-2121. PubMed ID: 34076966
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer.
Ramalingam SS; Foster J; Gooding W; Evans T; Sulecki M; Belani CP
Cancer; 2010 Mar; 116(5):1344-9. PubMed ID: 20082454
[TBL] [Abstract][Full Text] [Related]
11. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.
Ready N; Farago AF; de Braud F; Atmaca A; Hellmann MD; Schneider JG; Spigel DR; Moreno V; Chau I; Hann CL; Eder JP; Steele NL; Pieters A; Fairchild J; Antonia SJ
J Thorac Oncol; 2019 Feb; 14(2):237-244. PubMed ID: 30316010
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan-based chemotherapy in Chinese populations.
Ma X; Han S; Liu Y; Liu JT; Fang J; Zhang YH
J Pharm Pharmacol; 2020 Nov; 72(11):1528-1535. PubMed ID: 32737884
[TBL] [Abstract][Full Text] [Related]
13. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Morise M; Niho S; Umemura S; Matsumoto S; Yoh K; Goto K; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2014 Sep; 44(9):846-51. PubMed ID: 25057092
[TBL] [Abstract][Full Text] [Related]
14. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
Paz-Ares L; Spigel DR; Chen Y; Jove M; Juan-Vidal O; Rich P; Hayes T; Calderón VG; Caro RB; Navarro A; Dowlati A; Zhang B; Moore Y; Yao X; Kokhreidze J; Ponce S; Bunn PA
Cancer; 2022 May; 128(9):1801-1811. PubMed ID: 35195913
[TBL] [Abstract][Full Text] [Related]
15. Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.
Nakano S; Yuki S; Kawamoto Y; Nakatsumi H; Ando T; Kajiura S; Yoshikawa A; Harada K; Hatanaka K; Tanimoto A; Ishiguro A; Honda T; Dazai M; Sasaki T; Sakamoto N; Komatsu Y
Int J Clin Oncol; 2020 Oct; 25(10):1800-1806. PubMed ID: 32666389
[TBL] [Abstract][Full Text] [Related]
16. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
[TBL] [Abstract][Full Text] [Related]
17. Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer.
Lu H; Qin J; Han N; Xie F; Gong L; Li C
Integr Cancer Ther; 2018 Dec; 17(4):1109-1114. PubMed ID: 30229683
[TBL] [Abstract][Full Text] [Related]
18. Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer.
Lv C; Liu X; Zheng Q; Chen H; Yang X; Zhong J; Wang Y; Duan J; Wang Z; Bai H; Wu M; Zhao J; Wang J; Wang Z; An T; Zhuo M
Thorac Cancer; 2018 Sep; 9(9):1166-1173. PubMed ID: 30058109
[TBL] [Abstract][Full Text] [Related]
19. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan as a second-line monotherapy for small cell lung cancer.
Sevinc A; Kalender ME; Altinbas M; Ozkan M; Dikilitas M; Camci C;
Asian Pac J Cancer Prev; 2011; 12(4):1055-9. PubMed ID: 21790251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]